Assessing Post-Percutaneous Coronary Intervention Physiology: Is Hyperemia Necessary?

Allen Jeremias; Gregg W. Stone

doi:10.1016/j.jcin.2020.06.020

Assessing Post-Percutaneous Coronary Intervention Physiology: Is Hyperemia Necessary?

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	1934-1936
Number of pages	3
Journal	JACC: Cardiovascular Interventions
Volume	13
Issue number	16
DOIs	https://doi.org/10.1016/j.jcin.2020.06.020
State	Published - 24 Aug 2020

Keywords

coronary physiology
fractional flow reserve
percutaneous coronary intervention

Access to Document

10.1016/j.jcin.2020.06.020

Cite this

@article{88c6edaf11834a4da5aada6e68343e1a,

title = "Assessing Post-Percutaneous Coronary Intervention Physiology: Is Hyperemia Necessary?",

keywords = "coronary physiology, fractional flow reserve, percutaneous coronary intervention",

author = "Allen Jeremias and Stone, {Gregg W.}",

note = "Funding Information: Dr. Jeremias has received institutional funding (unrestricted education grant) from Volcano/Philips and Abbott Vascular; and served as a consultant for Volcano/Philips, Abbott Vascular, ACIST Medical, and Boston Scientific. Dr. Stone has received speaker or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; has served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and Cardiomech; and owns equity/options in Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. Funding Information: Dr. Jeremias has received institutional funding (unrestricted education grant) from Volcano/Philips and Abbott Vascular; and served as a consultant for Volcano/Philips, Abbott Vascular, ACIST Medical, and Boston Scientific. Dr. Stone has received speaker or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; has served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and Cardiomech; and owns equity/options in Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. ",

year = "2020",

month = aug,

day = "24",

doi = "10.1016/j.jcin.2020.06.020",

language = "English",

volume = "13",

pages = "1934--1936",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "16",

}

TY - JOUR

T1 - Assessing Post-Percutaneous Coronary Intervention Physiology

T2 - Is Hyperemia Necessary?

AU - Jeremias, Allen

AU - Stone, Gregg W.

N1 - Funding Information: Dr. Jeremias has received institutional funding (unrestricted education grant) from Volcano/Philips and Abbott Vascular; and served as a consultant for Volcano/Philips, Abbott Vascular, ACIST Medical, and Boston Scientific. Dr. Stone has received speaker or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; has served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and Cardiomech; and owns equity/options in Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. Funding Information: Dr. Jeremias has received institutional funding (unrestricted education grant) from Volcano/Philips and Abbott Vascular; and served as a consultant for Volcano/Philips, Abbott Vascular, ACIST Medical, and Boston Scientific. Dr. Stone has received speaker or other honoraria from Cook, Terumo, Qool Therapeutics, and Orchestra Biomed; has served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and Cardiomech; and owns equity/options in Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix.

PY - 2020/8/24

Y1 - 2020/8/24

KW - coronary physiology

KW - fractional flow reserve

KW - percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=85089236238&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2020.06.020

DO - 10.1016/j.jcin.2020.06.020

M3 - Editorial

C2 - 32819482

AN - SCOPUS:85089236238

SN - 1936-8798

VL - 13

SP - 1934

EP - 1936

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 16

ER -